Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 13/20 | 0.81 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14470653 | 0.90 | PYGM (1.00) | PYGMOPRM1OPRD1OPRK1HPGD | |
| SCHEMBL5550323 | 0.89 | PYGM (0.98) | PYGMOPRM1OPRD1OPRK1HPGD | |
| SCHEMBL5545757 | 0.87 | PYGM (1.00) | PYGMPPARGALDH1A1HPGDMAPT | |
| SCHEMBL14470642 | 0.83 | PYGM (1.00) | PYGMALDH1A1LMNA | |
| SCHEMBL5547110 | 0.82 | PYGM (0.87) | PYGMPPARGALDH1A1HPGDMAPT | |
| SCHEMBL14470664 | 0.79 | PYGM (1.00) | PYGMHPGDMAPTLMNA | |
| SCHEMBL5549625 | 0.77 | PYGM (0.81) | PYGMALDH1A1HPGDMAPTLMNA | |
| SCHEMBL5550231 | 0.76 | PYGM (1.00) | PYGMALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL14470666 | 0.76 | PYGM (1.00) | PYGMALDH1A1HPGDMAPTLMNA | |
| SCHEMBL5547056 | 0.76 | PYGM (1.00) | PYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1711184-B1 | (3-OXO-3,4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-18 | — | — | EP | claimed |